SS Innovations International, Inc. announced its unaudited financial results for the second quarter ended June 30, 2025, on August 7, 2025. The company reported record quarterly revenue of $10.0 million, a 121.7% increase from $4.51 million in the prior-year period.
System sales more than doubled to $8.78 million, and instrument sales surged by nearly 400% to $1.01 million. Gross profit more than tripled to $5.92 million from $1.44 million in Q2 2024, driven by higher revenue and significant gross margin expansion due to lower production costs. The net loss narrowed sharply to $256,691 from $4.14 million in Q2 2024.
For the first half of 2025, total revenue reached $15.12 million, an 85.5% increase over H1 2024. The company had installed over 100 SSi Mantra systems by July 2025, with over 5,000 surgical procedures performed. Based on recent FDA conversations, SS Innovations now expects to submit a 510(k) application for the SSi Mantra 3 by the end of September 2025, a potentially quicker pathway than the previously planned De Novo application, and continues to pursue EU CE Mark certification by late 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.